文献速递预防保健、筛查与疫苗常见症状与未分化疾病慢病管理

胰腺癌检测决策支持工具在澳大利亚基层医疗的外部验证:回顾性队列研究

Decision support tools for pancreatic cancer detection: external validation in Australian primary care - a retrospective cohort study.
PubMed 文献 · Br J Gen Pract · 2026-03-26

该回顾性队列研究利用澳大利亚维多利亚州链接的基层医疗与癌症登记数据,评估QCancer®、eRAT和QPaC Tool三种胰腺癌决策支持工具在识别未诊断胰腺癌患者中的性能。结果显示,胰腺癌患者诊断前更常见新发糖尿病、黄疸和意外体重下降(P<0.001);黄疸、脂肪泻和胰腺炎阳性预测值最高(分别为1.96%、1.77%、0.89%)。工具中eRAT的阳性预测值最高,为1.37%(95%CI=1.12–1.66),QPaC为1.01%(95%CI=0.82–1.22),QCancer®为0.8%(95%CI=0.54–1.15);结论认为这些工具在澳大利亚基层医疗数据中均未能强预测胰腺癌,整合额外数据的新诊断模型可能改善性能。

要点

  • 胰腺癌诊断前常见表现包括黄疸(29.0%)、腹痛(25.6%)、排便习惯改变(17.6%)和新发糖尿病(14.8%)。
  • 黄疸、脂肪泻和胰腺炎的阳性预测值分别为1.96%、1.77%和0.89%。
  • eRAT的阳性预测值最高(1.37%,95%CI=1.12–1.66),但三种工具预测能力均不强。

核心结论

  • 在澳大利亚基层医疗数据中,QCancer®、eRAT和QPaC Tool对胰腺癌的预测能力均不强。
  • 整合额外数据的新诊断模型可能改善预测性能。

研究设计与样本

  • 回顾性队列研究,使用澳大利亚维多利亚州链接的基层医疗与癌症登记数据。
  • 纳入因工具所列体征和/或症状至基层医疗就诊的患者。
  • 比较各工具及其单个症状/体征的诊断准确性统计量。

主要发现

  • 胰腺癌患者诊断前更常见新发糖尿病、黄疸和意外体重下降(P<0.001)。
  • 胰腺癌患者诊断前最常见表现为黄疸(29.0%)、腹痛(25.6%)、排便习惯改变(17.6%)和新发糖尿病(14.8%)。
  • 黄疸、脂肪泻和胰腺炎的阳性预测值分别为1.96%、1.77%和0.89%。
  • eRAT阳性预测值为1.37%(95%CI=1.12–1.66),QPaC为1.01%(95%CI=0.82–1.22),QCancer®为0.8%(95%CI=0.54–1.15)。

关键数值与推荐

  • 黄疸阳性预测值1.96%,脂肪泻1.77%,胰腺炎0.89%。
  • eRAT阳性预测值1.37%(95%CI=1.12–1.66)。
  • QPaC阳性预测值1.01%(95%CI=0.82–1.22)。
  • QCancer®阳性预测值0.8%(95%CI=0.54–1.15)。

临床怎么用

  • 在澳大利亚基层医疗中,不应仅依赖这些工具强预测胰腺癌。
  • 对出现黄疸、脂肪泻、胰腺炎、新发糖尿病或意外体重下降的患者应保持警惕。
  • 可考虑结合额外临床数据改进风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic cancer is often diagnosed at an advanced stage with poor survival. Risk assessment tools have been developed to aid early diagnosis of pancreatic cancer in primary care settings (QCancer®, electronic Risk Assessment Tool [eRAT], and the Queensland Institute of Medical Research [QIMR] Berghofer Pancreatic Cancer Decision Support Tool [QPaC Tool]) but have not been validated in the Australian setting. AIM: To estimate and compare the performance of these tools for identifying patients with undiagnosed pancreatic cancer using Australian primary care data. DESIGN AND SETTING: A cohort study was conducted using linked primary care and cancer registry data from Victoria, Australia. METHOD: Patients presenting to primary care with signs and/or symptoms included in the tools (recorded in the primary care 'reason for encounter') were included. Diagnostic accuracy statistics for each tool (and their individual signs and symptoms) were compared. RESULTS: Patients with pancreatic cancer were more likely (P<0.001) to present with new-onset diabetes, jaundice, and unexpected weight loss pre-diagnosis than patients without pancreatic cancer. The most common pre-diagnostic presentations in patients with pancreatic cancer were jaundice (29.0%), abdominal pain (25.6%), change in bowel habits (17.6%), and new-onset diabetes (14.8%). Jaundice, steatorrhoea, and pancreatitis had the highest positive predictive values (PPV) for pancreatic cancer (1.96%, 1.77%, and 0.89%, respectively). Among the tools, eRAT had the highest PPV of 1.37% (95% confidence interval [CI] = 1.12 to 1.66); the PPV for QPaC was 1.01% (95% CI = 0.82 to 1.22) and QCancer® was 0.8% (95% CI = 0.54 to 1.15). CONCLUSION: When applied to Australian primary care data, none of the tools were strongly predictive of pancreatic cancer. New diagnostic models incorporating additional data could potentially improve their predictive performance.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Schrader S, Rafiq M, Martinez-Gutierrez J, et al. Decision support tools for pancreatic cancer detection: external validation in Australian primary care - a retrospective cohort study. Br J Gen Pract. 2026. PMID: 41494778. doi:10.3399/BJGP.2025.0328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。